English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Major Depressant Disorder is one of the most common neuropsychiatric disorders and affects 17-20% of the world population. Despite scientific efforts, its treatment still presents itself with a limited efficacy and a delayed start-up effect. In this context, natural products are a potential source of new drugs. Riparin I (Rip I), one alcamide isolated from Aniba Riparia, has presented promising results. In pre-clinic trials, it has unchained predictive effects of antidepressant and anxiolytic activities in acute behavioral models of depression and anxiety. Objectives: Facing that, the goal of the trial was to investigate the activity of Riparin I in mice exposed to the model of chronic depression induced by corticosterone (Cort). Methods: Swiss female mice, weighting 22-25g, were divided as the following: control group (vehicle saline, 1% de tween80, 1% de DMSO, s.c., for 14 and 21 consecutive days), stressed group (CORT, 20mg/kg, s.c, for 14 or 21 days), group treated with RipI (50 mg/kg, orally, for 8 days), group treated with fluvoxamine (Flu 50 mg/kg, orally, for 8 days). Treatments started on the 14th day of corticosterone-induced stress until the 21st day. Behavior models analyzed were as follows: tail suspension (TS) and forced swim test (FS). The corticosterone treated group presented a greater immobility time (IT) than the control group (SC: Cont.: 45  7.30; CONT.: 108.9 3.5; p < 0.01). Meanwhile, the groups treated with RipI (50) and Flu(50) presented a smaller IT than the CORT group (SC: CONT.: 108.93.5; RipI: 49.576.6; Flu: 4213.3; p<0.01). Depressant behavior was unchanged by corticosterone administration and reverted using RipI and Flu. Conclusions: These results allow us to suggest a possible antidepressant effect of RipI in the corticosterone-induced animal depression model.

SCNS. 14. Evidence of antidepressant effect of Riparin I, isolated from Aniba riparia, in a model depression chronic in mice